QbD Group
    Request auditContact us
    Explore services by industry
    Residual Solvents Reports – Risk assessments for residual solvents in pharmaceutical products

    Residual Solvents Reports

    Risk assessments for residual solvents in pharmaceutical products

    QbD Group specializes in risk assessments for residual solvents in human and veterinary drug products, helping identify risks, generate comprehensive reports, and address regulatory concerns per ICH Q3C guidelines.

    What is residual solvent risk assessment?

    Residual solvent risk assessment is a comprehensive evaluation of drug substances, excipients, and manufacturing processes aimed at identifying and mitigating risks associated with residual solvents. This process is designed to protect patients from potential adverse effects.

    It includes three key steps:

    1. Analyzing potential residual solvents introduced during the manufacturing process.
    2. Evaluating actual or predicted solvent levels against established PDE values.
    3. Defining an effective control strategy based on the findings.

    Residual Solvents Reports — QbD Group

    The importance of managing residual solvents

    According to the ICH Q3C guideline, residual solvents offer no therapeutic benefit and can pose potential risks to patient safety.

    Patient safety

    Solvents must be removed to the greatest extent possible to protect patients.

    Regulatory compliance

    Meet product specifications, GMP, and other quality-based requirements.

    Audit readiness

    Updated, documented repository ensures preparedness for regulatory inspections.

    Product quality

    Maintain product integrity throughout the manufacturing process.

    How we work: our process for residual solvent risk assessment

    At QbD Group, we follow a structured approach to ensure a thorough and compliant residual solvent risk assessment.

    1. Initial consultation

    Understand your specific needs and regulatory concerns.

    2. Data collection

    Gather documentation regarding the drug product's manufacturing process.

    3. Risk assessment report

    Detailed report identifying potential sources of contamination per EMA guidelines.

    4. Report delivery

    Comprehensive report with solvent levels, PDE comparisons, and required controls.

    5. Follow-up support

    Ongoing support including acceptable limit calculations and detection limits.

    Residual Solvents Process — QbD Group
    QbD Group expertise

    Why QbD Group

    Your trusted partner

    Our EUROTOX-certified team ensures the highest standards of scientific quality in every residual solvent assessment.

    End-to-end toxicology support

    from early development to post-approval changes.

    Trusted expertise at scale

    decades of combined experience across diverse projects.

    Proactive compliance monitoring

    staying ahead of evolving solvent regulations.

    Certified Toxicology Experts

    EUROTOX-certified (ERT) toxicologists on every assessment.

    Let's talk Toxicology

    From risk assessments to regulatory compliance, our toxicology experts are ready to support your pharmaceutical needs.